<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360044</url>
  </required_header>
  <id_info>
    <org_study_id>2018 MRF Impact Award</org_study_id>
    <nct_id>NCT04360044</nct_id>
  </id_info>
  <brief_title>Cannabis for Acute Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial</brief_title>
  <official_title>Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Migraine Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD
      mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blind, randomized, crossover trial, subjects will treat 4 separate migraine
      attacks with 4 different treatments. Inhaled cannabis will be administered using a portable
      vaporization system (Mighty Medic; Storz &amp; Bickel) based on a validated Storz &amp; Bickel system
      and using a standardized inhalation approach. Subjects will self-administer inhaled cannabis
      as early as possible in the course of a migraine (see Procedure), taking 4 puffs of 1) THC,
      2) THC/CBD mix, 3) CBD, or 4) placebo. Patients will treat each of the 4 distinct migraine
      attacks with a different cannabis sample. Outcomes measured will include pain freedom and
      pain relief as well as presence or absence of photophobia, phonophobia, and nausea at 1 hour,
      2 hours (primary outcome), 24 hours, and 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blind, Placebo-controlled, Crossover Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Pain Relief at 2 Hours Post-Treatment</measure>
    <time_frame>2 Hours Post-Treatment</time_frame>
    <description>Dichotomous endpoint of pain reduction defined as reduction from moderate/severe pain to mild/no pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache pain freedom</measure>
    <time_frame>2 hours</time_frame>
    <description>Dichotomous endpoint of reduction from moderate/severe pain to no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most bothersome symptom freedom</measure>
    <time_frame>2 hours</time_frame>
    <description>Dichotomous endpoint of resolution of most bothersome symptom (of photophobia, phonophobia, and nausea) selected at the beginning of the migraine prior to cannabis administration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Headache pain relief</measure>
    <time_frame>1 hour, 24 hours, 48 hours</time_frame>
    <description>Dichotomous endpoint of reduction from moderate/severe pain to mild/no pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Headache pain freedom</measure>
    <time_frame>1 hour, 24 hours, 48 hours</time_frame>
    <description>Dichotomous endpoint of reduction from moderate/severe pain to no pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Most bothersome symptom freedom</measure>
    <time_frame>1 hour, 24 hours, 48 hours</time_frame>
    <description>Dichotomous endpoint of resolution of most bothersome symptom (of photophobia, phonophobia, and nausea) selected at the beginning of the migraine prior to cannabis administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from photophobia</measure>
    <time_frame>1 hour and 2 hours</time_frame>
    <description>Dichotomous endpoint of resolution of photophobia</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from phonophobia</measure>
    <time_frame>1 hour and 2 hours</time_frame>
    <description>Dichotomous endpoint of resolution of phonophobia</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>At any time over 48 hours</time_frame>
    <description>Dichotomous endpoint of use of rescue medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustained pain freedom</measure>
    <time_frame>24 hours and 48 hours</time_frame>
    <description>Dichotomous endpoint of absence of headache pain at 2 hours after dose, with no use of rescue medication and no relapse of headache pain</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustained most bothersome symptom freedom</measure>
    <time_frame>24 hours and 48 hours</time_frame>
    <description>Dichotomous endpoint of absence of most bothersome symptom at 2 hours afer dose, with no use of rescue medication and no relapse of most bothersome symptom</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Migraine</condition>
  <condition>Cannabis</condition>
  <condition>THC</condition>
  <condition>CBD</condition>
  <arm_group>
    <arm_group_label>THC ~4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 puffs of cannabis flower containing THC ~4% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THC ~4%/CBD ~6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 puffs of cannabis flower containing THC ~4% and CBD ~6% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD ~6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 puffs of cannabis flower containing CBD ~6% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Cannabis</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC ~4%</intervention_name>
    <description>4 puffs of vaporized flower containing THC ~4%</description>
    <arm_group_label>THC ~4%</arm_group_label>
    <other_name>THC</other_name>
    <other_name>delta 9-tetrahydrocannabinol</other_name>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD ~6%</intervention_name>
    <description>4 puffs of vaporized flower containing CBD ~6%</description>
    <arm_group_label>CBD ~6%</arm_group_label>
    <other_name>CBD</other_name>
    <other_name>cannabidiol</other_name>
    <other_name>hemp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC ~4% and CBD ~6%</intervention_name>
    <description>4 puffs of vaporized flower containing THC ~4% and CBD ~6%</description>
    <arm_group_label>THC ~4%/CBD ~6%</arm_group_label>
    <other_name>THC</other_name>
    <other_name>CBD</other_name>
    <other_name>delta 9-tetrahydrocannabinol</other_name>
    <other_name>cannabidiol</other_name>
    <other_name>marijuana</other_name>
    <other_name>hemp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Cannabis</intervention_name>
    <description>4 puffs of vaporized flower from which the THC and CBD have been extracted</description>
    <arm_group_label>Sham Cannabis</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 21 or ≤ 65

          -  Able to communicate in English

          -  Migraine, with or without aura, in its episodic or chronic manifestations, as per the
             International Headache Society (IHS) classification International Classification of
             Headache Disorders (ICHD-3) criteria (section 1.1, 1.2, 1.3).(48)

          -  Ability to provide informed consent and complete website questionnaires in English

          -  Prior THC-containing cannabis experience within the past two years

          -  Agrees not to use cannabis outside of the study during participation in the study

          -  Agrees not to use opioids or barbiturates during participation in the study

          -  Agrees not to drive a motor vehicle within 4 hours following last use of inhaled
             cannabis during participation in the study

        Exclusion Criteria:

          -  Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone prior
             to enrollment

          -  Pregnancy

          -  Breastfeeding

          -  Prisoner

          -  Known cognitive impairment

          -  Institutionalized

          -  Inability to complete 28-day headache diary

          -  Current moderate-severe or severe depression

          -  Current or past history of bipolar depression, schizophrenia, or psychosis

          -  Current or past history of cannabis, alcohol, opioid, or amphetamine abuse or other
             substance use disorder at the discretion of the research team

          -  Active pulmonary disease class IV heart failure, cirrhosis, or other severe medical
             illnesses at the discretion of the research team.

          -  Allergy or past adverse effects or negative past experiences from cannabis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie K Lam, MS, RN</last_name>
    <phone>858-822-0787</phone>
    <email>kklam@ucsd.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Nathaniel Schuster</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Cannabis</keyword>
  <keyword>THC</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be shared in a manner TBD based on funding availability and journal requirements.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 1 year and ending 5 years after article publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal. Proposals should be sent to nmschuster@health.ucsd.edu.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

